Status: Not yet recruiting
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants with R/R SCLC or select NECs
Participants needed: 110
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Moonlight Bio, IncUpdated: Jun 25, 2026Locations: 5
Eligibility criteria
≥18 years of age at the time of signing the ICF [+6]
Previous systemic anti-cancer therapies within the timeframes, as specified in t... [+15]